Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Insensitivity of oncogenic EGFR R776L mutation to EGFR inhibitors in lung cancer.

Lung cancer (Amsterdam, Netherlands) - 1 Mar 2024

Wang Yun, Hu Chen, Yu Hongwei, Hu Jie, Zhou Zhiwei, Fu Ning, Huang Xiang, Kong Fanhao, Wang Wenchao, Liu Jing

Abstract excerpt

Non-small cell lung cancers (NSCLC) account for 85 % of total lung cancers. Mutation in EGFRdrives the progress of NSCLSs with high mortality rate. Besides the common mutations in EGFR, which together comprise of 85 % of all EGFR mutations and respond to the targeted therapy of EGFR tyrosine kinase inhibitors (TKIs), many other low-frequency mutations of EGFR are existed in patients. The oncogenic roles and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mutation
Share to Acrylamides
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indoles

Share to Lung Neoplasms

Share to Pyrimidines

Source

Identifiers

PMID: 38335691
DOI: 10.1016/j.lungcan.2024.107495

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Insensitivity of oncogenic EGFR R776L mutation to EGFR inhibitors in lung cancer.PMID 38335691Read ↗

Response to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma with the Rare Epidermal Growth Factor Receptor Mutation S768I: a Retrospective Analysis and Literature Review.Semantic proximity Read ↗

Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution (Review).Semantic proximity Read ↗

Almonertinib and alflutinib show novel inhibition on rare EGFR S768I mutant cells.Semantic proximity Read ↗

Pulmonary Adenocarcinoma Patient with Complex Mutations on EGFR Benefits from Furmonertinib after Acquiring Gefitinib Resistance: A Case Report.Semantic proximity Read ↗

[Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer].Semantic proximity Read ↗

[Mechanism and clinical efficacy of third-generation epidermal growth factor receptor tyrosine kinase inhibitor in non-small cell lung cancer].Semantic proximity Read ↗

Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer.Semantic proximity Read ↗

[Advances on driver oncogenes of lung adenocarcinoma].Semantic proximity Read ↗

[A Rare Case of Lung Adenocarcinoma with EGFR L833V/H835L Co-mutation and Literature Review].Semantic proximity Read ↗

Clinicopathologic Features and Molecular Biomarkers as Predictors of Epidermal Growth Factor Receptor Gene Mutation in Non-Small Cell Lung Cancer Patients.Semantic proximity Read ↗

Response to tyrosine kinase inhibitors in lung adenocarcinoma with the rare epidermal growth factor receptor mutation S768I and G724S: A case report and literature review.Semantic proximity Read ↗

[Effectiveness of Tyrosine Kinase Inhibitors on Uncommon Epidermal Growth Factor Receptor Mutations in Non-small Cell Lung Cancer].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.